Mid-market

NB Private Debt Fund IV is already approaching the size of its predecessor, closed in 2019 at $1.7bn.

The partnership between Azimut Alternative Capital Partners and HighPost Capital will include “a capital-raising relationship,” sources told Buyouts.

Fund II will build on Orangewood’s deal-by-deal activity by investing in special situation and growth-oriented opportunities in non-discretionary healthcare, consumer and multi-unit sectors.

The amount raised so far already makes Fund V larger than its predecessor, which closed in 2017 at just over $1bn.

Jim Mahoney, Huron's new managing partner, spoke with Buyouts about how the firm's succession plan prepares it for the years ahead.

In a competitive US healthcare deal market, Accelmed's strategy puts it “below the radar of the big guns,” managing partner Uri Geiger told Buyouts.

At the original $1bn target and $1.5bn cap, the size of Fund V was already set to be larger than its 2018-vintage predecessor.

Avista Capital Partners IV was generating a 1.5x net investment multiple and 41% net internal rate of return as of September 2020, sources told Buyouts.

Fund III, launched last November, has to date secured more than $1.6bn, 24% above its original target.

Fund VI was “very significantly oversubscribed,” president and CEO Pascal Tremblay told Buyouts, with Novacap “more than doubling” the size of its investor base.